Residency · Residency · Urology

Interstitial Cystitis / Bladder Pain Syndrome

Introduction

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition defined by an unpleasant sensation, such as pain, pressure, or discomfort, perceived to originate from the urinary bladder. This sensation is accompanied by lower urinary tract symptoms that persist for more than six weeks without evidence of infection or other identifiable causes. In the United States, IC/BPS affects an estimated 3 to 8 million women and 1 to 4 million men. It is a diagnosis of exclusion that significantly impairs quality of life and poses considerable challenges in both diagnosis and management. Effective care requires a multimodal, patient-centered approach guided by phenotyping to tailor treatment strategies.

Definition and Terminology

The American Urological Association (AUA) defines IC/BPS as an unpleasant sensation related to the urinary bladder, associated with lower urinary tract symptoms lasting more than six weeks, in the absence of infection or other identifiable causes. The European Society for the Study of Interstitial Cystitis (ESSIC) classification further recognizes subtypes based on cystoscopic findings and histology. One subtype is the Hunner lesion subtype, which is characterized by a distinct inflammatory lesion and affects approximately 5 to 10% of patients; this subtype tends to respond better to lesion-directed therapy. The more common non-Hunner subtype, often referred to as bladder pain syndrome (BPS), exhibits a heterogeneous pathophysiology. Overall, IC/BPS likely represents a spectrum of disorders rather than a single disease entity.

Pathophysiology

The pathophysiology of IC/BPS involves multiple mechanisms. A key factor is urothelial dysfunction, specifically a deficiency of the glycosaminoglycan (GAG) layer that normally protects the bladder lining. This deficiency allows urinary solutes such as potassium and urea to penetrate the urothelium, triggering inflammation and pain. Mast cell activation is another important component; increased mast cell density in the detrusor muscle and suburothelium leads to the release of histamine, leukotrienes, and cytokines, which amplify inflammation. Neurogenic inflammation also plays a role, with upregulation of substance P and nerve growth factor (NGF) in the bladder wall sensitizing C-fiber afferents. Chronic afferent signaling results in central sensitization, a process of central pain amplification that can cause cross-organ sensitization and explains the frequent comorbidity with other pain syndromes. An autoimmune hypothesis is supported by the association of IC/BPS with other autoimmune conditions such as Sjogren syndrome, lupus, and inflammatory bowel disease. Hunner lesions represent a focal inflammatory lesion characterized by dense lymphoplasmacytic infiltrate, urothelial denudation, and granulation tissue.

<image>Cross-sectional diagram of the bladder wall comparing normal urothelium with intact GAG layer to the IC/BPS bladder showing GAG layer deficiency, increased urothelial permeability to urinary solutes (potassium ions), mast cell infiltration and degranulation in the lamina propria, and sensitized C-fiber nerve endings</image>

Clinical Presentation

Symptoms

Patients with IC/BPS typically experience bladder pain described as suprapubic pressure, discomfort, or pain that usually worsens with bladder filling and improves with voiding. Urinary frequency is often extreme, with some severe cases reporting 20 to 40 voids per day. Urgency is present but is driven by pain rather than detrusor overactivity. Nocturia is common and can significantly disrupt sleep. Women frequently report dyspareunia, particularly pain with deep penetration. Symptom flares are often triggered by dietary factors such as acidic foods, caffeine, alcohol, and artificial sweeteners, as well as by stress, hormonal changes, and sexual activity.

Associated Conditions

IC/BPS is commonly associated with chronic overlapping pain conditions including fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome, vulvodynia, temporomandibular disorder, and migraine. These associations suggest a shared mechanism involving central sensitization and dysfunction in pain processing. Comorbid anxiety and depression are also common and require concurrent management to optimize patient outcomes.

Diagnosis

Clinical Assessment

Diagnosis begins with a thorough history focusing on symptom duration, pain location and characteristics, voiding patterns, dietary triggers, sexual function, and the impact on quality of life. Validated questionnaires such as the O'Leary-Sant Symptom and Problem Index (ICSI/ICPI) and the Pelvic Pain and Urgency/Frequency (PUF) questionnaire are useful tools to quantify symptom severity and bother. Physical examination may reveal suprapubic tenderness and pelvic floor tenderness on vaginal or rectal exam, with assessment for pelvic floor myofascial dysfunction. A voiding diary can document frequency, voided volumes, and symptom correlation.

Laboratory and Diagnostic Studies

Urinalysis and urine culture are mandatory to exclude infection. Urine cytology should be performed if hematuria is present or if there are risk factors for bladder cancer. Measurement of post-void residual volume helps exclude urinary retention. Cystoscopy is not required for initial diagnosis but is recommended to identify Hunner lesions, which are present in 5 to 10% of patients. Hydrodistension under anesthesia may reveal glomerulations—petechial hemorrhages scattered across the mucosa—which are common but not specific to IC/BPS; Hunner lesions, however, are pathognomonic. Hydrodistension may also provide therapeutic benefit lasting weeks to months. Urodynamics are not routinely indicated but may show reduced bladder capacity and early sensory urgency; importantly, the absence of detrusor overactivity helps distinguish IC/BPS from overactive bladder (OAB). The potassium sensitivity test has largely been abandoned due to poor specificity and patient discomfort.

Differential Diagnosis

The differential diagnosis includes overactive bladder, urinary tract infection, bladder cancer, endometriosis, vulvodynia, chronic prostatitis/chronic pelvic pain syndrome (in men), radiation cystitis, and urethral diverticulum.

Management: AUA Guideline-Based Stepped Approach

First-Line Therapy: Education and Self-Care

Management begins with patient education, emphasizing that IC/BPS is a chronic condition requiring long-term management and setting realistic expectations. Dietary modification involves an elimination diet avoiding common triggers such as coffee, tea, alcohol, citrus fruits, tomatoes, spicy foods, and artificial sweeteners, followed by systematic reintroduction to identify individual sensitivities. Stress management techniques including relaxation, mindfulness, and cognitive behavioral therapy are important adjuncts. Pelvic floor physical therapy is a cornerstone of treatment, especially for patients with pelvic floor tenderness; it includes myofascial release, trigger point therapy, and biofeedback. Application of heat or cold to the perineum or suprapubic area may provide symptomatic relief.

Second-Line Therapy: Oral Medications

Oral medications include amitriptyline, a tricyclic antidepressant with analgesic, anticholinergic, and antihistamine properties, typically dosed at 25 to 75 mg at bedtime and supported by the most evidence among oral agents. Hydroxyzine, an H1 antihistamine targeting the mast cell component, is used at 25 to 75 mg at bedtime but offers only modest benefit. Cimetidine, an H2 receptor antagonist, has some evidence for symptom improvement. Pentosan polysulfate sodium (Elmiron), a synthetic GAG analog and the only FDA-approved oral medication for IC, requires 3 to 6 months to achieve effect. However, long-term use beyond three years carries a risk of pigmentary maculopathy, necessitating ophthalmologic screening and tempering enthusiasm for this agent.

Third-Line Therapy: Intravesical Treatments

Intravesical therapies include dimethyl sulfoxide (DMSO), which is FDA-approved and possesses anti-inflammatory, analgesic, and muscle relaxant properties; it is administered in six-week cycles. Intravesical heparin replenishes the GAG layer and is often combined with lidocaine for "rescue instillations." Lidocaine cocktails containing lidocaine, heparin, and sometimes sodium bicarbonate are used for acute flares. Hydrodistension performed under anesthesia provides modest and temporary benefit, with greater efficacy in the Hunner lesion subtype. Other agents such as intravesical hyaluronic acid and chondroitin sulfate aim to replenish the GAG layer, though evidence for their effectiveness is mixed.

<image>Cystoscopic images showing three key findings in IC/BPS: (A) a classic Hunner lesion appearing as a reddened, friable inflammatory patch on the bladder wall, (B) glomerulations (petechial hemorrhages diffusely scattered across the mucosa after hydrodistension), and (C) normal-appearing bladder mucosa for comparison, with labels and annotations</image>

Fourth-Line Therapy

For patients with the Hunner lesion subtype, fulguration or triamcinolone injection of lesions is highly effective, although lesions may recur and require repeat treatment. Intradetrusor injection of botulinum toxin A (onabotulinumtoxinA) at doses of 100 to 200 units can reduce pain and urinary frequency but carries a risk of urinary retention that may necessitate clean intermittent catheterization.

Fifth-Line Therapy

Cyclosporine A, an immunosuppressive agent, is reserved for refractory cases due to its significant side effect profile. Sacral neuromodulation (InterStim) may improve frequency and pain in selected patients.

Sixth-Line Therapy

Urinary diversion with or without cystectomy is considered a last resort for intractable, debilitating disease. Substitution cystoplasty may provide benefit but is irreversible and has variable outcomes. Extensive counseling regarding the irreversibility and uncertain outcomes of these surgical options is mandatory.

Key Clinical Pearls

IC/BPS is fundamentally a diagnosis of exclusion, so infection, malignancy, and other identifiable causes must always be ruled out first. Pelvic floor physical therapy is an underutilized first-line intervention that benefits the majority of patients. The Hunner lesion subtype, present in 5 to 10% of patients, represents a distinct inflammatory phenotype that responds well to lesion-directed fulguration or steroid injection. Long-term use of pentosan polysulfate requires ophthalmologic surveillance due to the risk of pigmentary maculopathy. The best outcomes are achieved with multimodal therapy combining behavioral, pharmacologic, and physical therapy approaches. It is also essential to screen for and address comorbid anxiety, depression, and chronic overlapping pain conditions to optimize patient care.

References

1. Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545-1553.
2. Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2022;208(1):34-42.
3. Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology. 2018;125(11):1793-1802.
4. Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57(1):35-48.

Read this lecture as Markdown